Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2013-03
Metadata
Show full item recordCitation
J. Clin. Microbiol. 2013, 51 (3):841-8Abstract
Candidemia is often a life-threatening infection, with highly variable incidence among countries. We conducted a nationwide study of candidemia in Iceland from 2000 to 2011, in order to determine recent trends in incidence rates, fungal species distribution, antifungal susceptibility patterns, and concurrent antifungal consumption. A total of 208 infection episodes in 199 patients were identified. The average incidence during the 12 years was 5.7 cases/100,000 population/year, which was significantly higher than that from 1990 to 1999 (4.3/100,000/year; P = 0.02). A significant reduction in the use of blood cultures was noted in the last 3 years of the study, coinciding with the economic crisis in the country (P < 0.001). Age-specific incidence rates were highest among patients at the extremes of age, 20.7/100,000 for <1 year of age and 18.1/100,000 for >60 years, and varied by gender. Age-specific incidence among males >80 years old was 28.6/100,000/year, and it was 8.3/100,000/year for females in this age group (P = 0.028). The 30-day survival rate among adult patients remained unchanged compared to that from 1990 to 1999 (70.4% versus 69.5%, P = 0.97). Candida albicans was the predominant species (56%), followed by C. glabrata (16%) and C. tropicalis (13%). The species distribution remained stable compared to that from previous decades. Fluconazole use increased 2.4-fold from 2000 to 2011, with no increase in resistance. In summary, the incidence of candidemia in Iceland has continued to increase but may have reached a steady state, and no increase in antifungal drug resistance has been noted. Decreased use of blood cultures toward the end of the study may have influenced detection rates.Description
To access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.Additional Links
http://dx.doi.org/10.1128/JCM.02566-12Rights
Archived with thanks to Journal of clinical microbiologyae974a485f413a2113503eed53cd6c53
10.1128/JCM.02566-12
Scopus Count
Collections
Related articles
- Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme.
- Authors: Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaeldgaard P, Knudsen JD, Kristensen L, Leitz C, Lemming LE, Nielsen L, Olesen B, Rosenvinge FS, Røder BL, Schønheyder HC
- Issue date: 2013 Aug
- Epidemiology, risk factor, species distribution, antifungal resistance and outcome of Candidemia at a single French hospital: a 7-year study.
- Authors: Tadec L, Talarmin JP, Gastinne T, Bretonnière C, Miegeville M, Le Pape P, Morio F
- Issue date: 2016 May
- Candida orthopsilosis fungemias in a Spanish tertiary care hospital: incidence, epidemiology and antifungal susceptibility.
- Authors: Blanco-Blanco MT, Gómez-García AC, Hurtado C, Galán-Ladero MA, Lozano Mdel C, García-Tapias A, Blanco MT
- Issue date: 2014 Apr-Jun
- Candidaemia in Sweden: a nationwide prospective observational survey.
- Authors: Ericsson J, Chryssanthou E, Klingspor L, Johansson AG, Ljungman P, Svensson E, Sjölin J
- Issue date: 2013 Apr
- Candidemia surveillance in Iowa: emergence of echinocandin resistance.
- Authors: Matsumoto E, Boyken L, Tendolkar S, McDanel J, Castanheira M, Pfaller M, Diekema D
- Issue date: 2014 Jun